Welcome to the New Mexico Chapter of the American College of Cardiology
ACC Live Courses For a listing of all ACC Live Courses please visit: https://www.acc.org/education-and-meetings/meetings |
Please join your cardiology colleagues at the ACC Rockies Chapter Meeting in Park City, Utah for updates on ACC affairs, the potential new CV Board, and clinical topics such as Genetic and Sports EP, plus a discussion on the growing role of obesity medications in heart failure, and the first-ever Cardiology State-of-the-State report. There will be many opportunities for networking, as well!.
For more information and to register, please visit: 
Latest in Cardiology from ACC.org
- How Do the 2025-2030 Dietary Guidelines For Americans Measure Up For Cardiovascular Health?The Dietary Guidelines for Americans (DGA), released jointly by the secretaries of the U.S. Department of Health and Human Services (HHS) and U.S. Department of Agriculture (USDA) every 5 years, are a major driver of food policy, diet quality, and cardiovascular (CV) health in the population.
- ACCEL Lite: SURPASS-CVOT: Effect of Tirzepatide Versus Dulaglutide on MACEIn this interview, Dipti Itchhaporia MD, MACC and Stephen Nicholls, MBBS, PhD, FACC discuss the SURPASS-CVOT Trial (Effect of Tirzepatide Versus Dulaglutide on Major Adverse Cardiovascular Events).
- REUP For DCD Feasible Regardless of Donor Age, Ischemic TimeRapid recovery with extended ultraoxygenated preservation (REUP) for donation after circulatory death (DCD) was found to be feasible regardless of donor age and ischemic time, according to a study published Jan. 26 in JAMA.
- Can Patient-Specific Registration of Jeopardized and Viable Segments Guide Revascularization?Patient-specific registration of segmental jeopardy and viability is a feasible strategy to identify patients with ischemic cardiomyopathy (ICM) who benefit from early revascularization, according to a recent study published in JACC: Cardiovascular Imaging.
- The Role of Exercise in Cardio-OncologyAs cancer survival rates improve due to advances in treatment, new challenges have emerged; one of the most serious is cancer therapy–related cardiac dysfunction (CTRCD) and subsequent cardiovascular disease (CVD) among survivors of cancer.